Ariel E Feldstein1, Daniel Hartmann2, Benedikt Kaufmann1,3, Agustina Reca1, Baocai Wang3, Helmut Friess3. 1. Department of Pediatric Gastroenterology, University of California San Diego (UCSD), La Jolla, CA, USA. 2. Department of Surgery, TUM School of Medicine, Klinikum rechts der Isar, Technical University of Munich, 81675, Munich, Germany. daniel.hartmann@tum.de. 3. Department of Surgery, TUM School of Medicine, Klinikum rechts der Isar, Technical University of Munich, 81675, Munich, Germany.
Abstract
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) has become the most common form of chronic liver disease in both adults and children worldwide. Understanding the pathogenic mechanisms behind NAFLD provides the basis for identifying risk factors, such as metabolic syndrome, pancreatoduodenectomy, and host genetics, that lead to the onset and progression of the disease. The progression from steatosis to more severe forms, such as steatohepatitis, fibrosis, and cirrhosis, leads to an increased number of liver and non-liver complications. PURPOSE: NAFLD-associated end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC) often require surgery as the only curative treatment. In particular, the presence of NAFLD together with the coexisting metabolic comorbidities that usually occur in these patients requires careful preoperative diagnosis and peri-/postoperative management. Bariatric surgery, liver resection, and liver transplantation (LT) have shown favorable results for weight loss, HCC, and ESLD in patients with NAFLD. The LT demand and the increasing spread of NAFLD in the donor pool reinforce the already existing lack of donor organs. CONCLUSION: In this review, we will discuss the diverse mechanisms underlying NAFLD, its implications for surgery, and the challenges for patient management.
BACKGROUND:Nonalcoholic fatty liver disease (NAFLD) has become the most common form of chronic liver disease in both adults and children worldwide. Understanding the pathogenic mechanisms behind NAFLD provides the basis for identifying risk factors, such as metabolic syndrome, pancreatoduodenectomy, and host genetics, that lead to the onset and progression of the disease. The progression from steatosis to more severe forms, such as steatohepatitis, fibrosis, and cirrhosis, leads to an increased number of liver and non-liver complications. PURPOSE:NAFLD-associated end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC) often require surgery as the only curative treatment. In particular, the presence of NAFLD together with the coexisting metabolic comorbidities that usually occur in these patients requires careful preoperative diagnosis and peri-/postoperative management. Bariatric surgery, liver resection, and liver transplantation (LT) have shown favorable results for weight loss, HCC, and ESLD in patients with NAFLD. The LT demand and the increasing spread of NAFLD in the donor pool reinforce the already existing lack of donor organs. CONCLUSION: In this review, we will discuss the diverse mechanisms underlying NAFLD, its implications for surgery, and the challenges for patient management.
Authors: Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal Journal: Hepatology Date: 2017-09-29 Impact factor: 17.425
Authors: Elizabeth M Brunt; Vincent W-S Wong; Valerio Nobili; Christopher P Day; Silvia Sookoian; Jacquelyn J Maher; Elisabetta Bugianesi; Claude B Sirlin; Brent A Neuschwander-Tetri; Mary E Rinella Journal: Nat Rev Dis Primers Date: 2015-12-17 Impact factor: 52.329
Authors: Laia Bertran; Rosa Jorba-Martin; Andrea Barrientos-Riosalido; Marta Portillo-Carrasquer; Carmen Aguilar; David Riesco; Salomé Martínez; Margarita Vives; Fàtima Sabench; Daniel Del Castillo; Cristóbal Richart; Teresa Auguet Journal: Int J Mol Sci Date: 2022-07-04 Impact factor: 6.208
Authors: Frankangel Servin; Jarrod A Collins; Jon S Heiselman; Katherine C Frederick-Dyer; Virginia B Planz; Sunil K Geevarghese; Daniel B Brown; Michael I Miga Journal: Front Physiol Date: 2022-02-03 Impact factor: 4.566
Authors: Noha M Hany; Sanaa Eissa; Manal Basyouni; Amany H Hasanin; Yasmin M Aboul-Ela; Nagwa M Abo Elmagd; Iman F Montasser; Mahmoud A Ali; Paul J Skipp; Marwa Matboli Journal: J Transl Med Date: 2022-07-30 Impact factor: 8.440
Authors: Ana Luisa Ordoñez-Vázquez; Eva Juárez-Hernández; Julia María Zuarth-Vázquez; Martha Helena Ramos-Ostos; Misael Uribe; Graciela Castro-Narro; Iván López-Méndez Journal: Int J Environ Res Public Health Date: 2022-09-27 Impact factor: 4.614